

---

*Research Article: New Research | Cognition and Behavior*

## **Chemogenetic silencing of prelimbic cortex to anterior dorsomedial striatum projection attenuates operant responding**

<https://doi.org/10.1523/ENEURO.0125-19.2019>

**Cite as:** eNeuro 2019; 10.1523/ENEURO.0125-19.2019

Received: 31 March 2019

Revised: 28 August 2019

Accepted: 3 September 2019

---

*This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.*

**Alerts:** Sign up at [www.eneuro.org/alerts](http://www.eneuro.org/alerts) to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2019 Shipman et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1 Chemogenetic silencing of prelimbic cortex to anterior dorsomedial striatum projection  
2 attenuates operant responding

3

4 Abbreviated title: PL to aDMS silencing attenuates operant responding

5

6 Megan L. Shipman<sup>1,2</sup>, Gregory C. Johnson<sup>1,2</sup>, Mark E. Bouton<sup>1</sup>, & John T. Green<sup>1</sup>

7

8 <sup>1</sup>University of Vermont Department of Psychological Science

9

<sup>2</sup>Neuroscience Graduate Program

10 MS, MB, and JG designed research, MS and GJ performed research, MS, GJ, and JG analyzed  
11 data, MS, JG, GJ, and MB wrote the paper

12

13 Correspondence should be addressed to:

14 John T. Green

15 Department of Psychological Science

16 2 Colchester Ave.

17 University of Vermont

18 Burlington, VT 05405

19 e-mail: john.green@uvm.edu

20

21 Number of figures: 5

Number of words for abstract: 255

22 Number of tables: 0

Number of words for significance  
statement: 44

23

24 Number of multimedia: 0

Number of words for introduction: 538

25

Number of words for discussion: 1643

26

27 Acknowledgements: We would like to thank David J. Bucci, Todd A. Clason, and Anthony D.  
28 Morielli for their help with DREADDs, and Callum Thomas for his help with microscopy.

29 Authors report no conflict of interest.

30 Funding sources: University of Vermont College of Arts and Sciences Seed Grant Award.

31

## 32 Abstract

33 Operant (instrumental) conditioning is a laboratory analog for voluntary behavior and  
34 involves learning to make a response for a reinforcing outcome. The prelimbic cortex (PL), a  
35 region of the rodent medial prefrontal cortex, and the dorsomedial striatum (DMS), have been  
36 separately established as important in the acquisition of minimally-trained operant behavior.  
37 Despite dense anatomical connections between the two regions, experimenters have only  
38 recently linked projections from the PL to the posterior DMS in the acquisition of an operant  
39 response. Yet, it is still unknown if these projections mediate behavioral expression, and if more  
40 anterior regions of the DMS (aDMS), which receive dense projections from the PL, are also  
41 involved. Therefore, we utilized designer receptors exclusively activated by designer drugs  
42 (DREADDs) to test whether or not projections from the PL to the anterior DMS influence the  
43 expression of operant behavior. Rats underwent bilateral PL-targeted infusions of either a  
44 DREADD virus (AAV8-hSyn-hM4D(Gi)-mCherry) or a control virus (AAV8-hSyn-GFP). In  
45 addition, guide cannulae were implanted bilaterally in the aDMS. Rats were tested with both  
46 CNO (DREADD ligand) and vehicle infusions into the aDMS. Animals that had received the  
47 DREADD virus, but not the control virus, showed attenuated responding when they received  
48 CNO microinfusions into the aDMS, compared to vehicle infusions. Patch clamp  
49 electrophysiology verified the inhibitory effect of CNO on DREADDs-expressing PL neurons in  
50 acute brain slices. GFP-expressing control PL neurons were unaffected by CNO. The results add  
51 to the recent literature suggesting that connections between the PL and aDMS are important for  
52 the expression of minimally-trained operant responding.

53

54 Significance statement

55 Only very recently has it been shown that prelimbic cortex projections to the posterior  
56 dorsomedial striatum are important in the acquisition of operant responding. Here, we show that  
57 prelimbic cortex projections to the *anterior* dorsomedial striatum are important in the *expression*  
58 of operant responding.

59

60 Chemogenetic silencing of prelimbic cortex to anterior dorsomedial striatum projection  
61 attenuates operant responding

62 Introduction

63 The prelimbic cortex (PL) has been well established as a mediator of operant  
64 (instrumental) responses early in training (Corbit and Balleine, 2003; Killcross and Coutureau,  
65 2003; Ostlund and Balleine, 2005; Tran-Tu-Yen et al., 2009; Trask et al., 2017; Shipman et al.,  
66 2018). The dorsomedial striatum (DMS) has similarly been implicated in the acquisition and  
67 expression of operant responding, with a particular emphasis on the posterior DMS (pDMS) (Yin  
68 et al., 2005a; Yin et al., 2005b; Shiflett et al., 2010). Because the PL and pDMS have both been  
69 implicated in the early acquisition of operant responding, it has been suggested that they may  
70 function together as part of a greater circuit supporting goal-directed operant responding (Corbit,  
71 2018). Indeed, pharmacological disconnection of these two regions prior to acquisition sessions  
72 disrupts the expression of operant responding at test (Hart et al., 2018a).

73 Traditional disconnection studies do not address the question of whether or not function  
74 is mediated by a direct vs. an indirect connection between two brain regions. Recent research  
75 using Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) has shown that  
76 PL to pDMS projections are important for the acquisition of operant responding (Hart et al.,  
77 2018b). Hart, Balleine, and colleagues utilized a dual-virus approach to inactivate the PL-pDMS  
78 pathway by infusing AAV-Cre recombinase into the pDMS, and a Cre-dependent DREADDs  
79 viral construct into the PL. They found that silencing the PL-pDMS pathway during acquisition,  
80 via systemic injection of the DREADDs ligand clozapine-N-oxide (CNO), reduced operant  
81 responding during test (Hart et al., 2018b).

82           The PL has been implicated in the expression of minimally-trained operant responding  
83 when testing occurs in the acquisition context (Trask et al., 2017; Shipman et al., 2018).  
84 Temporary inactivation of the PL with baclofen/muscimol at the time of test following six daily  
85 sessions of acquisition (lever press training) resulted in an attenuation of operant responding in  
86 the context where training had been conducted, but not in another context (Trask et al., 2017).  
87 Hart et al. (2018) showed that PL projections to posterior DMS are important in the acquisition  
88 of operant behavior, but they did not examine whether PL projections to the DMS are important  
89 for the expression of operant behavior. In addition, Hart et al. did not examine the function of PL  
90 projections to the anterior DMS (aDMS); some studies suggest that PL projections to the anterior  
91 DMS (aDMS) are at least as dense as PL projections to pDMS (Mailly et al., 2013; Hunnicut et  
92 al., 2016).

93           In the current experiment, we hypothesized that PL projections to the anterior DMS are  
94 involved in the expression of operant responding in the acquisition context. Six weeks prior to  
95 training, we infused an AAV8-DREADDs or control viral construct bilaterally into the PL and  
96 implanted bilateral guide cannulae into the aDMS. Rats underwent six days of instrumental  
97 conditioning followed by infusion of CNO or vehicle into the anterior DMS prior to test. We  
98 found that silencing projections from the PL to a relatively anterior region of the DMS attenuated  
99 lever-press responding, implicating this pathway in the expression of operant responding. Patch-  
100 clamp electrophysiology in a separate group of rats confirmed that CNO suppressed spiking in  
101 DREADDs-expressing, layer 5 PL pyramidal neurons but not in PL neurons that expressed the  
102 control, GFP, construct.

103

104 Methods

105 "All animal procedures were performed in accordance with the [Author University] animal care  
106 committee's regulations."

107 Subjects

108 The subjects were 24 male Wistar rats from Charles River Laboratories (St. Constance,  
109 Quebec). Rats were 59-63 days old and initially housed in pairs upon arrival. They were given at  
110 least 3 days to acclimate to the colony before undergoing surgery. Following surgery, rats were  
111 housed individually in a room maintained on a 12:12-h light: dark cycle. Experimentation  
112 occurred during the light portion of the cycle.

113 Surgery

114 Rats were anaesthetized with isoflurane. pAAV8-hSyn-hM4D(Gi)-mCherry viral  
115 construct (gift from Bryan Roth; Addgene plasmid # 50475 ; <http://n2t.net/addgene:50475> ;  
116 RRID:Addgene\_50475) or the control pAAV8-hSyn-EGFP viral construct (gift from Bryan  
117 Roth; Addgene plasmid # 50465 ; <http://n2t.net/addgene:50465> ; RRID:Addgene\_50465) was  
118 infused bilaterally into the PL with a Hamilton syringe (stereotaxic coordinates AP: +3.0, ML:  
119 +/-0.75, DV: -4.0) at a rate of 0.1µl/min. Each side received an infusion of 0.8µl. The needle was  
120 in place for two minutes prior to the start of the infusion to allow the brain to settle, and 10  
121 minutes following completion of the infusion to allow for diffusion away from the needle tip.  
122 Guide cannulae (22 gauge, Plastics One) were targeted bilaterally to the anterior DMS at  
123 stereotaxic coordinates AP: +1.0, ML:+/-2.0, DV: -3.6. Rats were given carprofen (5.0 mg/kg)  
124 for analgesia, as well as bupivacaine around the scalp incision, and Ringer's solution (1.0ml)  
125 following surgery. A second dose of carprofen was administered the following day. Rats were

126 weighed and reduced to 90% free feeding weight four days prior to magazine training, and were  
127 maintained at 90% free feeding weight throughout the experiment.

#### 128 Apparatus

129 Two sets of four operant chambers were utilized for this experiment (Med Associates  
130 model ENV-008-VP, St. Albans, VT). The sets were separated by room and differed slightly in  
131 their features. Differentiation of contexts was not required for this experiment, but rats were  
132 counterbalanced on vector type and the contexts where they received training/testing. Operant  
133 chambers measured 30.5 x 24.1 x 21.0 cm (l x w x h) and the food cup (measuring 5.1 x 5.1 cm)  
134 was located within the center of the front wall at a height of 2.5 cm above the floor. All  
135 chambers also featured a lever to the left of the magazine (Med Associates model ENV-112CM)  
136 that was inserted following a time-out period of two minutes at the beginning of each session.  
137 Within each room, each of the four chambers was housed in a sound attenuation chamber. Each  
138 chamber was lit by a single incandescent bulb (7.5 W) located on the sound attenuation chamber  
139 ceiling. Ventilation fans provided white noise (65 dBA).

140 Half the operant chambers featured clear, acrylic plastic on the walls and a ceiling with  
141 brushed aluminum on the front and rear walls. Floor panels were stainless steel grids (0.48 cm  
142 diameter) that were staggered so that every other bar was in the opposite of two planes from the  
143 previous bar (one plane was 0.5 cm above the other). The other half of the chambers had all floor  
144 grids mounted in the same plane with each bar spaced 1.6 cm from the previous bar. The walls in  
145 these boxes were also acrylic plastic but featured black, diagonal stripes that were 3.8 cm wide  
146 and 3.8 cm apart.

147 The reinforcer utilized for this experiment was a 45-mg sucrose pellet (5-TUT:1811251,  
148 TestDiet, Richmond, IN). The pellet was delivered to the magazine by instruction through a  
149 computer located in an adjacent room.

#### 150 Procedure

151 All behavioral procedures were conducted so that both tests occurred 6-7 weeks  
152 following vector infusion. Rats were run in cohorts of 4 or 8 and counterbalanced across  
153 conditions.

#### 154 Magazine training

155 All rats received one half-hour session of magazine training. Once all animals were  
156 placed in their respective operant chambers, a two-minute time-out period began. During this  
157 period, no reinforcers were available. Following that, sucrose reinforcers were freely delivered to  
158 the food magazine on a RT 30 schedule. No levers were present during this training.

#### 159 Acquisition training

160 Rats then received six daily acquisition sessions. At the start of each session, once all rats  
161 were in their respective operant chambers, left levers were inserted into boxes after two min and  
162 rats were reinforced on a VI-30 schedule for lever presses. Levers retracted following completion  
163 of the half hour session. If rats initially failed to eat sucrose pellets, levers were baited with  
164 mashed pellets. One rat had to be removed from further analysis because it failed to eat any  
165 pellets and thus failed to acquire the operant lever-pressing response.

#### 166 Test

167           After acquisition, all rats underwent two test sessions, separated by a day of retraining.  
168   Prior to the first test session, half the rats received a 0.5  $\mu$ l bilateral intracranial infusion of CNO  
169   (1.0 mM) and the other half received a vehicle infusion (artificial CSF (ACSF)) into the DMS  
170   (see slice preparation section for more specifics about ACSF composition). The CNO  
171   concentration of 1 mM was based on previous studies (Mahler et al., 2014; Lichtenberg et al.,  
172   2017). For infusions, dummy cannulae were removed and internal cannulae were inserted into  
173   guide cannulae. Internal cannulae tips protruded 1 mm below the tip of guide cannulae. Infusions  
174   were delivered over 2 minutes (0.25  $\mu$ l/minute) by internal cannulae attached to tubing  
175   (Intramedic) that connected to Hamilton syringes driven by a microinfusion pump (Kd  
176   Scientific). Internal cannulae were allowed to remain in place for one minute following infusions  
177   before removal and reinsertion of dummy cannulae. Rats were then placed in transport containers  
178   and put into operant chambers 5-15 min after the infusion. After a 2-min period, levers were  
179   inserted into the operant chambers (as usual). The test ran for 10 min; lever press responses had  
180   no scheduled consequences (i.e., the test was conducted in extinction). The following day, rats  
181   received a session of retraining with the VI-30 reinforcement schedule. A second test was given  
182   the day after, in which rats received the opposite infusion of the first test. Other than receiving  
183   the opposite infusate, testing proceeded exactly as on the first test day.

#### 184   Histology

185           Following the second test, rats were injected with a lethal dose of sodium pentobarbital  
186   (150 mg/kg, i.p.) and transcardially perfused with phosphate-buffered saline (PBS) followed by  
187   4% paraformaldehyde. Brains were removed and postfixed for one hour before being transferred  
188   to a 30% sucrose/PBS solution. After sinking, brains were embedded in OCT and flash-frozen in  
189   2-methyl butane that had been cooled with dry ice. The PL and DMS of each brain were

190 sectioned at 60 $\mu$ m and floated in phosphate buffer onto slides. Sections were dried in the dark  
191 before being mounted with Vectashield mounting medium with DAPI and coverslipped. Viral  
192 transfection was examined using a confocal microscope (Nikon C-2) (see representative images  
193 in Figures 2 and 3). Excitation lasers were 405 nm (DAPI), 488 nm (EGFP) and 561 nm  
194 (mCherry). Viral expression was examined for accuracy by comparing the location of PL cell  
195 expression to the PL location in a rat brain atlas (Paxinos and Watson, 2014). Axon terminals  
196 were examined for expression directly underneath the deepest part of the cannulae, which were  
197 confirmed to be in the DMS.

#### 198 Slice Preparation for Electrophysiology

199 Adult Wistar rats, of the same age and from the same supplier as above, were used for  
200 patch clamp electrophysiology. Rats underwent PL infusion of viral construct AAV8-hSyn-  
201 hM4D(Gi)-mCherry or AAV8-hSyn-EGFP as described above. Following at least six weeks of  
202 recovery, electrophysiology experiments were performed. On the experimental day, rats were  
203 deeply anesthetized with sodium pentobarbital and transcardially perfused with cold, sucrose-  
204 replaced artificial cerebrospinal fluid. The brain was then quickly removed and sliced in the  
205 coronal plane on a Leica VT1000S (Leica Instruments) vibratome. Brain slices were then  
206 allowed to recover in warmed sucrose-replaced artificial cerebrospinal fluid at 32 $^{\circ}$  C for 30  
207 minutes, and then equilibrated in room temperature artificial cerebrospinal fluid (ACSF) for at  
208 least 30 minutes prior to recording. ACSF was composed of the following in mM: NaCl (124),  
209 KCl (2.8), CaCl (2), NaH<sub>2</sub>PO<sub>4</sub> (1.25), Glucose (10), Sodium Ascorbate (0.4), Sodium Pyruvate  
210 (2), MgSO<sub>4</sub> (2), and NaHCO<sub>3</sub> (26). Sucrose-replaced ACSF was similar to recording-ACSF with  
211 the following exceptions in mM: NaCl (0), Sucrose (206), CaCl (1), MgCl (1). Each was pH  
212 adjusted to 7.3-7.4 with HCl and osmolarity was 310  $\pm$  5 mOsm.

## 213 Recording Procedures

214 Slices were transferred to a recording chamber (Warner Instruments) and continuously  
215 perfused with oxygenated, 32° C ACSF at a rate of 3-4 ml/minute. Virally-infected cells were  
216 identified under fluorescent illumination in layer 5 of the PL (Figures 5B and 5D) using a Leica  
217 DM-LFSA microscope and Rolera Bolt 3000 CCD camera. Cells were then patched under  
218 brightfield/infrared illumination in current clamp mode. Electrodes were made from thin-walled  
219 borosilicate glass capillaries (World Precision Instruments) and pulled on a Sutter P-97  
220 micropipette puller and filled with a K-glu intracellular solution composed of the following in  
221 mM: potassium gluconate (140), KCl (2), MgCl (3), HEPES (10), Phosphocreatine (5), K-ATP  
222 (2), Na-GTP (0.2) and pH adjusted to 7.3-7.4. Cells were clamped with a Multiclamp 700B  
223 controller and Multiclamp software (Molecular Devices). Data from patched cells was acquired  
224 using a Digidata 1440 interface (Molecular Devices) and pClamp software (Molecular Devices).  
225 Patched neurons equilibrated for approximately 5 minutes following successful whole cell  
226 configuration. Access resistance was monitored throughout experiments and if it reached above  
227 25 MΩ, or changed by > 20%, recordings were discarded. Patched neurons were considered  
228 acceptably healthy with a resting membrane potential below -50 mV and an action potential  
229 overshoot greater than +10 mV. Excitability curves were generated by injecting progressively  
230 larger positive current at 50 pA increments from 0-450 pA at the highest level of stimulation and  
231 counting the number of spikes at each level. This was done prior to CNO exposure, and after 4-6  
232 minutes of 10 μM CNO exposure. Spike curves were analyzed using Clampfit software  
233 (Molecular Devices).

## 234 Statistical analysis

235 IBM SPSS 25.0 was used for data analysis. A repeated measures ANOVA was used to  
236 examine responses per minute across acquisition sessions and test sessions. The rejection  
237 criterion was set at  $p < 0.05$ . Following a significant interaction, within-subjects comparisons  
238 (two-tailed paired-samples t-tests) were performed to determine the source of the interaction.  
239 Effect size was calculated as Cohen's  $d$  for all significant effects (see Table 1) (Cohen, 1988;  
240 Rosenthal, 1994).

#### 241 Results

242 Four rats (2 DREADD, 2 GFP) were removed prior to analysis: one rat did not acquire  
243 the lever-press response, two rats had a viral vector infusion site dorsal to the PL, and one rat had  
244 extensive cannula-related damage to the DMS (see further explanation in histology section).  
245 This left 10 rats in each group.

#### 246 Acquisition

247 All rats increased responding (lever presses/minute) across training sessions, indicating  
248 successful learning of the operant response (see Figure 1A). A 2 (Vector: DREADD vs GFP) x 6  
249 (session) repeated-measures ANOVA yielded a main effect of session,  $F(5,90) = 56.18$ ,  $MSE =$   
250  $9.78$ ,  $p < .001^a$ , but no main effect of vector or a vector x session interaction ( $F$ 's  $< 1$ ).

#### 251 Test

252 Inactivation of the PL-anterior DMS pathway attenuated the expression of operant  
253 responding during the test (see Figure 1B). A 2 (Vector: DREADD vs GFP) x 2 (Drug: CNO vs  
254 vehicle) repeated-measures ANOVA yielded a significant vector x drug interaction,  $F(1,18) =$   
255  $5.08$ ,  $MSE = 1.95$ ,  $p = 0.04^b$ . Follow-up paired-samples t-tests compared lever-press responding  
256 after CNO vs vehicle for each vector group separately. The DREADD group showed an

257 attenuation of responding when tested with a CNO infusion,  $t(9) = 2.36, p = 0.04^c$ . In contrast, the  
258 rats that had received the GFP vector showed no difference in responding following CNO vs  
259 vehicle infusions into the DMS,  $t(9) = 1.31, p = 0.22^d$ . The pattern indicates that intra-DMS CNO  
260 effects were selective to the rats that had received PL DREADD transfection.

#### 261 Histology

262 DREADD-mCherry expression and control GFP expression were verified in the cell  
263 bodies of the PL and axon terminals of the DMS in all rats. Examples are shown in Figure 2.  
264 Examples are also shown of typical dorsal-ventral and posterior-most spread from the PL  
265 infusion site (Figure 3). Two rats were removed because the viral-vector infusion site in the PL  
266 was too shallow. Cannula placements in the DMS were also verified (Figure 4). No rats had to  
267 be excluded from analysis for incorrect cannula placement, though one brain showed extensive  
268 damage from a cannula (possibly from infection) that affected tissue well beyond the cannula  
269 tract and DMS. This rat was excluded from analysis. Thus, three rats were removed during  
270 verification of viral expression, leaving the DREADD group with a final  $n$  of 10 and the GFP  
271 group with a final  $n$  of 10.

#### 272 Electrophysiology

273 To confirm the effect of CNO on DREADDs-expressing PL pyramidal neurons, we used  
274 whole-cell patch-clamp electrophysiology to compare spike activity (number of spikes to 10  
275 current steps, 0-450 pA) before and after CNO exposure (see Figure 5). DREADDs-expressing  
276 PL neurons showed fewer spikes than non-expressing neurons after CNO exposure. In contrast,  
277 non-DREADDs expressing PL neurons spiked slightly more after CNO exposure, possibly  
278 because of CNO suppression of nearby DREADDs-expressing inhibitory interneurons.

279 A 2 (Drug: CNO vs vehicle) x 10 (Current: 0-450 pA) repeated-measures ANOVA on  
280 DREADDs-expressing PL neurons revealed a significant main effect of CNO on neuron spiking,  
281  $F(1, 4) = 7.83$ ,  $MSE = 31.49$ ,  $p = 0.049^e$ , and a significant drug x current interaction,  $F(9, 36) =$   
282  $4.52$ ,  $MSE = 2.82$ ,  $p = 0.001^e$ . Follow-up paired-samples t-tests comparing CNO vs. vehicle at  
283 each current step revealed significantly fewer spikes with CNO at current steps of 200-, 250-,  
284 and 300-pA ( $p$ 's  $< 0.046^f$ ) (see Figure 5A). The same analyses on GFP-expressing PL neurons  
285 revealed no CNO or drug x current interaction effects,  $p$ 's  $> 0.45$  (see Figure 5C).

## 286 Discussion

287 The present results suggest that PL projections to a relatively anterior region of the DMS  
288 are involved in the expression of operant responding. This finding expands upon the work by  
289 Trask et al. (2017) that had found involvement of the PL in expression of operant responding in  
290 the same paradigm, as well as that of Hart et al. (2018), who demonstrated a role for PL-to-  
291 *posterior* DMS projections in the *acquisition* of goal-directed operant responding. The current  
292 results contrastingly show that a PL-to-a more *anterior* DMS pathway is important in the  
293 *expression* of operant responding early in training. This is unlikely to be a motor-related effect,  
294 given that studies have demonstrated that pharmacological inactivation of the PL (and therefore  
295 all of its projections) reduces only minimally-trained responding, and only in the acquisition  
296 context, while leaving other responses unaffected (Killcross and Coutureau, 2003; Trask et al.,  
297 2017; Shipman et al., 2018). Finally, we confirmed with *ex vivo* patch-clamp electrophysiology  
298 that cells in layer 5 of the PL expressing the DREADD-mCherry construct reporter showed  
299 attenuated spiking in the presence of CNO. Spiking of PL neurons expressing only the control  
300 GFP reporter was unaffected by CNO.

301            Though statistically significant, the size of the reduction in responding was numerically  
302 small in our DREADDs-expressing rats. However, there are several important points to keep in  
303 mind. First, we inactivated only a subset of projections from the PL to the aDMS, and the  
304 inactivation was probably less than total, as suggested by our electrophysiology results. Second,  
305 it is likely that other PL projections, besides just those to the aDMS, are important in expression  
306 of minimally-trained operant responding in the acquisition context; indeed, others (Trask et al.,  
307 2017) have shown a fairly large attenuation of responding with pharmacological inactivation of  
308 PL, which would inactivate all PL projections. Finally, it is worth comparing the magnitude of  
309 our effects to those of Hart et al., (2018), who used a dual-vector approach and intraperitoneal  
310 injections of CNO during acquisition to silence PL-pDMS projections. Hart et al. (2018) reported  
311 that in a 5-min choice (still-valued R2 vs. devalued R1) test session, DREADDs-expressing rats  
312 that had received vehicle injection prior to acquisition sessions emitted an average of  
313 approximately 18 R2 lever-presses; a separate group of DREADDs-expressing rats that had  
314 received CNO injection prior to acquisition sessions emitted an average of approximately 12 R2  
315 lever-presses. This translates to a reduction of approximately 1 lever-press per min. We found  
316 that during a 10-min test session, vehicle-infused DREADDs-expressing rats emitted an average  
317 of approximately 86 responses while CNO-infused DREADDs-expressing rats emitted an  
318 average of approximately 76 responses. This also translates to a reduction of 1 lever-press per  
319 min. Thus, despite a difference in methods and DMS terminal locations, the magnitude of  
320 operant response reduction as a result of DREADDs-mediated inactivation of PL-DMS terminals  
321 was similar in Hart et al. (2018) and our experiment.

322            A recent concern with the use of DREADDs is that CNO does not appear to cross the  
323 blood-brain barrier; instead, the effects of systemic injections of CNO may be via the CNO

324 metabolite clozapine, which binds with high affinity to DREADDs and binds with endogenous  
325 receptors (Gomez et al., 2017). We avoided this issue here by using intracranial CNO infusions.  
326 However, there may still be off-target effects caused by the use of a relatively high concentration  
327 of CNO in this method (Gomez et al., 2017). Therefore, we included two control procedures: (1)  
328 a group of rats that did not express DREADDs and (2) all rats received CNO and vehicle, in  
329 separate tests. Thus, we controlled for CNO effects as well as for potential vector effects. We  
330 also note here that an additional caveat to circuit-specific manipulation using DREADDs is that  
331 it may be difficult to completely isolate a specific pathway. For example, collateral projections of  
332 projection neurons expressing DREADDs may also be activated/inactivated by CNO. However,  
333 it is unclear how likely this is given that CNO is infused directly into the DMS.

334         We verified that CNO reduced spiking in PL neurons expressing DREADDs-mCherry  
335 while having no effect on spiking in PL neurons expressing GFP. However, this leaves  
336 unaddressed the question of whether or not CNO reduced spiking in DMS neurons as a result of  
337 reducing spiking in PL neurons projecting to the DMS. It seems likely that it did: first, the most  
338 straightforward interpretation of our behavioral results is that intra-DMS CNO reduced  
339 activation of PL projections to the DMS, which in turn reduced DMS activation. It is unlikely  
340 that CNO affected DMS neurons directly, since rats that did not express DREADDs were  
341 unaffected by intra-DMS CNO. Second, Lichtenberg et al. (2017) co-expressed the same  
342 DREADDs-mCherry construct as we used, along with channelrhodopsin, in neurons in the  
343 orbitofrontal cortex (OFC) and patch-clamped neurons in the basolateral amygdala (BLA) that  
344 were nearby fluorescing OFC terminals. Excitatory post-synaptic currents in these BLA neurons,  
345 produced by optical activation of fluorescing OFC terminals, were reduced in the presence of  
346 CNO. This suggests that CNO does reduce axon terminal activity in this DREADDs-mCherry

347 construct. In addition, the design of our behavioral experiment makes alternative explanations  
348 less likely.

349 Like Hart et al. (2018), we examined a role for PL-to-DMS projections in minimally  
350 trained operant responding, though our methods differ on a few critical points. First, we only  
351 trained one response with one outcome. Hart et al. trained two lever-press responses, each with  
352 its own unique outcome, and both levers were available during (choice) testing. Second, we did  
353 not devalue our reinforcer; thus we did not distinguish between goal-directed vs. habitual  
354 behavior. Third, we examined the PL-DMS pathway in a more anterior portion of the DMS (e.g.,  
355 guide cannula implanted at +1.0 mm AP from bregma in our study vs. AAV-Cre infusion at -0.4  
356 to -0.5 mm AP in Hart et al., 2018b), rather than the PL projections to posterior DMS regions  
357 that have been more frequently associated with acquisition of goal-directed behavior. Fourth, we  
358 examined expression of responding, rather than the acquisition of responding, by inactivating the  
359 PL-DMS pathway prior to test rather than prior to each acquisition session. Finally, we utilized a  
360 different means of pathway-specific chemogenetic inactivation, implanting cannulae into the  
361 DMS to inactivate PL axon terminals after AAV8-DREADD infusion into the PL. In contrast,  
362 Hart et al. utilized a dual-virus approach, infusing a Cre-dependent DREADD viral construct into  
363 the PL and a Cre recombinase viral construct into the pDMS, and then inactivating the PL-pDMS  
364 pathway with intraperitoneal injection of CNO. Overall, our findings complement those of Hart  
365 et al. (2018) who showed that the PL-pDMS pathway is important for the acquisition of goal-  
366 directed behavior. We show here that the PL-aDMS pathway is important for expression of  
367 minimally-trained operant behavior.

368 Many of the studies investigating the role of the PL in operant behavior have additionally  
369 confirmed whether responding was goal-directed or habitual (Corbit and Balleine, 2003;

370 Killcross and Coutureau, 2003; Ostlund and Balleine, 2005; Tran-Tu-Yen et al., 2009; Shipman  
371 et al., 2018). Behavior is considered goal-directed if it is sensitive to reinforcer devaluation,  
372 whereas habitual behavior is insensitive to reinforcer devaluation. Though we did not utilize  
373 reinforcer devaluation to examine if our behavior was goal-directed, it is reasonable to assume  
374 that our minimally-trained operant response was goal-directed, as habit typically develops across  
375 many training sessions (Dickinson, 1985). This is further supported by the findings of Shipman  
376 et al. (2018), who showed that the PL plays a transitory role in the development of operant  
377 responding: inactivation of PL reduced minimally-trained goal-directed instrumental behavior,  
378 but not more extensively-trained instrumental behavior that is goal-directed. The PL has never  
379 been linked to habit.

380         Despite dense anatomical connections from the PL to the aDMS, research has tended to  
381 focus on the pDMS in goal-directed behavior. The pDMS has been defined as the DMS  
382 beginning around +0.24 mm anterior to bregma (Hart and Balleine, 2017). The focus on the  
383 pDMS is largely based on an early study by Yin and colleagues (Yin et al., 2005b). Yin et al.  
384 (2005) found that pre-training or post-training lesions of the posterior region of the DMS  
385 impaired the acquisition and expression of goal-directed behavior (target posterior coordinates at  
386 -0.4 mm AP relative to bregma, compared to +1.0 mm AP in the current study). However, the  
387 effects of aDMS lesions were actually somewhat inconclusive, as pre-training aDMS lesions did  
388 not affect expression of goal-directed behavior at test but post-training aDMS lesions did. Other  
389 research has provided support for the idea that the pDMS, but not the aDMS, is important for  
390 goal-directed responding. For example, functional disconnection of the parafascicular thalamus  
391 and pDMS disrupts goal-directed responding, whereas disconnection of the parafascicular  
392 thalamus and aDMS has no effect (Bradfield et al., 2013).

393           Nonetheless, other studies have found that the aDMS, in addition to the pDMS, is  
394 important for goal-directed behavior. Corbit and Janak (2010) trained two different lever-press  
395 responses and then used satiation to devalue the outcome associated with one response. They  
396 found that temporary inactivation with baclofen/muscimol of either the anterior DMS or  
397 posterior DMS (coordinates at +1.2 mm and -0.3 mm AP relative to bregma, respectively) during  
398 acquisition resulted in insensitivity to outcome devaluation at time of test in an operant task  
399 (Corbit and Janak, 2010). This result suggests that aDMS and pDMS both seem to be involved in  
400 goal-directed responding. Further studies by this lab also showed a role for the anterior DMS in  
401 goal-directed behavior with an alcohol reinforcer (Corbit et al., 2012). Thus, there is some  
402 evidence for aDMS involvement in goal-directed behavior despite a literature that focuses  
403 largely on the pDMS.

404           In conclusion, we found that the PL-aDMS pathway is important in the expression of  
405 operant responding. Thus, we expand upon previous research to show, using circuit-specific  
406 chemogenetic silencing, a role for a PL-to-anterior DMS pathway in the expression of operant  
407 behavior to complement the demonstrated role of a PL-to-posterior DMS pathway in the  
408 acquisition of operant behavior.

409

## 410 References

- 411 Bradfield LA, Bertran-Gonzalez J, Chieng B, Balleine BW (2013) Thalamostriatal pathway and  
412 cholinergic control of goal-directed action: Interlacing new with existing learning in the  
413 striatum. *Neuron* 79:153-166.
- 414 Cohen J (1988) *Statistical Power Analysis for the Behavioral Sciences*, 2nd Edition. Hillsdale,  
415 NJ: Erlbaum.
- 416 Corbit LH (2018) Understanding the balance between goal-directed and habitual behavioral  
417 control. *Current Opinion in Behavioral Sciences* 20:161-168.
- 418 Corbit LH, Balleine BW (2003) The role of the prelimbic cortex in instrumental conditioning.  
419 *Behavioural Brain Research* 146:145-157.
- 420 Corbit LH, Janak PH (2010) Posterior dorsomedial striatum is critical for both selective  
421 instrumental and Pavlovian reward learning. *European Journal of Neuroscience* 31:1312-  
422 1321.
- 423 Corbit LH, Nie H, Janak PH (2012) Habitual alcohol seeking: Time course and the contribution  
424 of subregions of the dorsal striatum. *Biological Psychiatry* 72:389-395.
- 425 Dickinson A (1985) Actions and habits: The development of behavioural autonomy.  
426 *Philosophical Transactions of the Royal Society B: Biological Sciences* 308:67-78.
- 427 Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ,  
428 Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A, Michaelides M (2017)  
429 Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.  
430 *Science* 357:503-507.
- 431 Hart G, Balleine BW (2017) Medial striatum. In: *Encyclopedia of Animal Cognition and*  
432 *Behavior* (Vonk J, Shackelford, eds). Basel, Switzerland: Springer International  
433 Publishing.
- 434 Hart G, Bradfield LA, Balleine BW (2018a) Prefrontal cortico-striatal disconnection blocks the  
435 acquisition of goal-directed action. *Journal of Neuroscience* 38:1311-1322.
- 436 Hart G, Bradfield LA, Fok SY, Chieng B, Balleine BW (2018b) The bilateral prefronto-striatal  
437 pathway is necessary for learning new goal-directed actions. *Curr Biol* 28:1-12.
- 438 Hunnicut BJ, Jongbloets BC, Birdsong WT, Gertz KJ, Zhong H, Mao T (2016) A comprehensive  
439 excitatory input map of the striatum reveals novel functional organization. *eLife*  
440 5:e19103.
- 441 Killcross S, Coutureau E (2003) Coordination of actions and habits in the medial prefrontal  
442 cortex of rats. *Cerebral Cortex* 13:400-408.
- 443 Lichtenberg NT, Pennington ZT, Holley SM, Greenfield VY, Cepeda C, Levine MS, Wassum  
444 KM (2017) Basolateral amygdala to orbitofrontal cortex projections enable cue-triggered  
445 reward expectations. *Journal of Neuroscience* 37:8374-8384.
- 446 Mahler SV, Vazey EM, Beckley JT, Keistler CR, McGlinchey EM, Kaufling J, Wilson SP,  
447 Deisseroth K, Woodward JJ, Aston-Jones G (2014) Designer receptors show role for  
448 ventral pallidum input to ventral tegmental area in cocaine seeking. *Nat Neurosci* 17:577-  
449 585.
- 450 Maily P, Aliane V, Groenwegen HJ, Haber SN, Deniau J-M (2013) The rat prefrontalstriatal  
451 system analyzed in 3D: Evidence for multiple interacting functional units. *Journal of*  
452 *Neuroscience* 33:5718-5727.
- 453 Ostlund SB, Balleine BW (2005) Lesions of the medial prefrontal cortex disrupt the acquisition  
454 but not the expression of goal-directed learning. *Journal of Neuroscience* 25:7763-7770.

- 455 Paxinos G, Watson C (2014) *The Rat Brain in Stereotaxic Coordinates*, 7th Edition. London,  
456 UK: Academic Press.
- 457 Rosenthal R (1994) Parametric measures of effect size. In: *The Handbook of Research Synthesis*  
458 (Cooper H, Hedges LV, eds). New York, NY: Sage.
- 459 Shiflett MW, Brown RA, Balleine BW (2010) Acquisition and performance of goal-directed  
460 instrumental actions depends on ERK signaling in distinct regions of dorsal striatum in  
461 rats. *Journal of Neuroscience* 30:2951-2959.
- 462 Shipman ML, Trask S, Bouton ME, Green JT (2018) Inactivation of prelimbic and infralimbic  
463 cortex respectively affects minimally-trained and extensively-trained goal-directed  
464 actions. *Neurobiology of Learning and Memory* 155:164-172.
- 465 Tran-Tu-Yen DAS, Marchand AR, Pape J-R, DiScala G, Coutureau E (2009) Transient role of  
466 the rat prelimbic cortex in goal-directed behaviour. *European Journal of Neuroscience*  
467 30:464-471.
- 468 Trask S, Shipman ML, Green JT, Bouton ME (2017) Inactivation of the prelimbic cortex  
469 attenuates context-dependent operant responding. *Journal of Neuroscience* 37:2317-2324.
- 470 Yin HH, Knowlton BJ, Balleine BW (2005a) Blockade of NMDA receptors in the dorsomedial  
471 striatum prevents action-outcome learning in instrumental conditioning. *European*  
472 *Journal of Neuroscience* 22:505-512.
- 473 Yin HH, Ostlund SB, Knowlton BJ, Balleine BW (2005b) The role of the dorsomedial striatum  
474 in instrumental conditioning. *European Journal of Neuroscience* 22:513-523.
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491

492 Table 1. Data structure, type of test used to analyze the data, and observed power of key results.

	Data Structure	Type of test	Power (Cohen's d)
a	Normal distribution	Repeated Measures ANOVA	Main effect Session: 1.784
b	Normal distribution	Repeated Measures ANOVA	Interaction (Drug x Vector): 0.247
c	Normal distribution	Paired Samples <i>T</i> test	Main effect Drug: 0.745
d	Normal distribution	Paired Samples <i>T</i> test	Not significant
e	Normal distribution	Repeated Measures ANOVA	Main effect CNO: 0.388 Interaction (Drug x Current): 0.262
f	Normal distribution	Paired samples <i>T</i> tests	Main effects Current: 200 pA: 1.204 250 pA: 3.095 300 pA: 2.807

493

494


495

496

497


498

499 Figure 1: A. Acquisition of lever-press response over six training sessions with one retraining  
500 session in between the two test sessions. Mean  $\pm$  SEM. B. Test session results for rats that had  
501 received the DREADD or control (GFP) construct in the prelimbic cortex. CNO or vehicle was  
502 infused into the aDMS prior to the first test session, and rats received the opposite infusate prior  
503 to the second test session. Order of infusion was counterbalanced in each group. \* =  $p < 0.05$ .




504

505 Figure 2. A. Location (left panel) and representative images (right panels) of cell bodies  
506 expressing DREADDs-mCherry construct (left) or GFP control construct (right) in the PL (area  
507 32) at 40x. Blue is DAPI nuclear stain. B. Location (left panel) and representative images (right  
508 panels) of axon terminals in anterior DMS expressing DREADDs-mCherry (left) or GFP (right)  
509 at 60x. Scale bars are 50  $\mu$ m.




510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528

529 Figure 3: Location and representative DREADDs-mCherry (A) and GFP (B) spread in the  
530 prelimbic cortex (area 32) at 20x. Top panels are the infusion site and bottom panels are  
531 estimated posterior-most spread. Stitching was done with a 3% overlap in the images and each  
532 frame within the final image was 2048 x 2048 pixels. Scale bars = 100  $\mu$ m.  
533




534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556

557 Figure 4. Left panel. Infusion sites in anterior DMS. Numbers are anterior-posterior distance in  
558 mm from bregma. Right panel. Example cannula placement. Shown is the right hemisphere. CN  
559 = guide cannula track. Guide cannula tips were above the DMS. The thin white bar shows  
560 where the infusion cannula (which protruded 1 mm below the tip of the guide cannula) was.  
561 STR = striatum. LV = lateral ventricle. Scale bar = 500  $\mu$ m.  
562





563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581


582 Figure 5: A. Excitability curve shows spikes elicited to progressively larger current injection of  
 583 DREADDs-mCherry-expressing PL pyramidal cells before and after CNO (10  $\mu$ M) exposure. B.  
 584 Example image of DREADDs-mCherry-expressing PL pyramidal cell in fluorescent (left), and  
 585 infrared (right). C. Excitability curve shows spikes elicited to progressively larger current  
 586 injection of GFP-expressing PL pyramidal cells before and after CNO (10  $\mu$ M) exposure. B.  
 587 Example image of GFP-expressing PL pyramidal cell in fluorescent (left), and infrared (right). E.  
 588 Example trace of DREADDs-expressing PL neuron; 4 minutes of CNO exposure caused a  
 589 reduction in spike frequency to current injection compared to baseline, while removal of CNO  
 590 from the bath caused a partial recovery of spike frequency. Scale bars are 20 mV and 100 ms,  
 591 and stimulation was 250 pA and 350 pA for 1 second.




592












+1.6  
+1.2  
+1.0  
+0.7  
+0.48  
+0.2




**A** AAV-HM4Di/mCherry infected PL Neurons




**C** AAV-GFP infected PL Neurons



**B**



**D**



**E**

